Edition:
United States

Kamada Ltd (KMDA.OQ)

KMDA.OQ on NASDAQ Stock Exchange Global Select Market

4.96USD
3:59pm EST
Change (% chg)

$-0.13 (-2.55%)
Prev Close
$5.09
Open
$5.00
Day's High
$5.01
Day's Low
$4.96
Volume
9,907
Avg. Vol
4,451
52-wk High
$6.43
52-wk Low
$4.30

Latest Key Developments (Source: Significant Developments)

Kamada Announces Collaboration With Hospitals To Evaluate Its Product For Preemption Of Type Of Graft-Versus-Host Disease
Thursday, 4 Jan 2018 07:00am EST 

Jan 4 (Reuters) - Kamada Ltd ::KAMADA ANNOUNCES COLLABORATION WITH A CONSORTIUM OF PROMINENT HOSPITALS LED BY THE MOUNT SINAI HOSPITAL TO EVALUATE ITS ALPHA-1 ANTITRYPSIN PRODUCT FOR PREEMPTION OF STEROID REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE.KAMADA SAYS ANNOUNCED COLLABORATION WITH MOUNT SINAI ACUTE GVHD INTERNATIONAL CONSORTIUM.KAMADA LTD - RECEIVED EXCLUSIVE RIGHTS TO DEVELOP AND COMMERCIALIZE ALPHA-1 ANTITRYPSIN FOR PREEMPTION OF GVHD USING MAGIC BIOMARKERS.KAMADA SAYS STUDY OF ALPHA-1-ANTITRYPSIN WILL BE INITIATED IN Q1 OF 2018.KAMADA LTD - TOP-LINE RESULTS FROM ALPHA-1-ANTITRYPSIN STUDY ARE EXPECTED TO BE AVAILABLE IN SECOND HALF OF 2019.  Full Article

Kamada announces new supply agreement with international organization for KamRAB
Tuesday, 21 Nov 2017 07:00am EST 

Nov 21 (Reuters) - Kamada Ltd :Kamada announces new supply agreement with international organization for KamRAB for post-exposure prophylaxis against rabies infection.Kamada Ltd - the ‍three-year supply agreement will extend through 2020, and is expected to generate revenues for Kamada of approximately $13 million​.  Full Article

Kamada and ‍Chiesi Farmaceutici terminate European distribution agreement for inhaled alpha-1 antitrypsin therapy
Monday, 20 Nov 2017 07:00am EST 

Nov 20 (Reuters) - Kamada Ltd ::Kamada Ltd - Co, ‍chiesi Farmaceutici S.P.A. mutually agree to terminate European distribution agreement for inhaled alpha-1 antitrypsin therapy.Kamada Ltd - ‍Kamada now maintains full, worldwide commercial rights to its inhaled aat​.Kamada - ‍ no financial implications related to termination of agreement for inhaled alpha-1 antitrypsin therapy.  Full Article

No consensus analysis data available.